2013 ; 23(9):
|Author||Seong-Won Song, Song-Jae Lee, Chang-Young Kim, Jae-Kyung Song, Eui-Jung Jung, Yong Bock Choi, Sung-Won Min, Jong-Won Oh|
|Affiliation||Graduate Program in Biomaterials Science and Engineering, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-749, Republic of Korea,Bioresearch Institute, Yooyoung Pharmaceuticals Co. Ltd., Guro-dong, Gur-gu, Seoul, 152-719, Republic of Korea|
|Title||Inhibition of Tumor Growth in a Mouse Xenograft Model by the Humanized Anti-HGF Monoclonal Antibody YYB-101 Produced in a Large-Scale CHO Cell Culture|
J. Microbiol. Biotechnol.2013 ; 23(9):
|Abstract||The humanized anti-hepatocyte growth factor (HGF) monoclonal antibody (mAb) YYB-101 is
a promising therapeutic candidate for treating various cancers. In this study, we developed a
bioprocess for large-scale production of YYB-101 and evaluated its therapeutic potential for
tumor treatment using a xenograft mouse model. By screening diverse chemically defined
basal media formulations and by assessing the effects of various feed supplements and
feeding schedules on cell growth and antibody production, we established an optimal medium
and feeding method to produce 757 mg/l of YYB-101 in flask cultures, representing a 7.5-fold
increase in titer compared with that obtained under non-optimized conditions. The optimal
dissolved oxygen concentration for antibody production was 70% pO2. A pH shift from 7.2 to
7.0, rather than controlled pH of either 7.0 or 7.2, resulted in productivity improvement in 5 L
and 200 L bioreactors, yielding 737 and 830 mg/ml of YYB-101, respectively. The YYB-101
mAb highly purified by affinity chromatography using a Protein A column and two-step ion
exchange chromatography effectively neutralized HGF in a cell-based assay and showed
potent tumor suppression activity in a mouse xenograft model established with human
|Keywords||Chinese hamster ovary cells, anti-human hepatocyte growth factor monoclonal ant, humanized antibody, process development, anti-HGF antibody YYB-101, anti-tumor activity|
Borset M, Waage A, Sundan A. 1996. Hepatocyte growth factor reverses the TGF-beta-induced growth inhibition of CCL-64 cells. A novel bioassay for HGF and implications for the TGF-beta bioassay. J. Immunol. Methods 189: 59-64.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. 1991. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251: 802-804.
Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, et al. 2006. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66: 1721-1729.
Butler M. 2005. Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl. Microbiol. Biotechnol. 68: 283-291.
Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, et al. 2001. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA 98:7443-7448.
Cherrington JM, Strawn LM, Shawver LK. 2000. New paradigms for the treatment of cancer: the role of antiangiogenesis agents. Adv. Cancer Res. 79: 1-38.
Comoglio PM, Giordano S, Trusolino L. 2008. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov. 7: 504-516.
Franek F, Hohenwarter O, Katinger H. 2000. Plant protein hydrolysates: preparation of defined peptide fractions promoting growth and production in animal cells cultures. Biotechnol. Prog. 16: 688-692.
Gawlitzek M, Estacio M, Furch T, Kiss R. 2009. Identification of cell culture conditions to control N-glycosylation siteoccupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol. Bioeng. 103: 1164-1175.
Giordano S. 2009. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr. Opin. Mol. Ther. 11: 448-455.
Heidemann R, Zhang C, Qi H, Larrick Rule J, Rozales C, Park S, et al. 2000. The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells. Cytotechnology 32: 157-167.
Higuchi O, Mizuno K, Vande Woude GF, Nakamura T. 1992. Expression of c-met proto-oncogene in COS cells induces the signal transducing high-affinity receptor for hepatocyte growth factor. FEBS Lett. 301: 282-286.
Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. 2005. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53: 35-69.
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. 2008. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68: 4360-4368.
Kim K, Hur Y, Ryu EK, Rhim JH, Choi CY, Baek CM, et al. 2007. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet. Biochem. Biophys. Res. Commun. 354: 115-121.
Kim KJ, Wang L, Su YC, Gillespie GY, Salhotra A, Lal B, et al. 2006. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 12: 1292-1298.
Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T. 2000. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res. 60: 6737-6743.
Kunkel JP, Jan DC, Jamieson JC, Butler M. 1998. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol. 62: 55-71.
Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. 2006. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. 12: 6144-6152.
Matsumoto K, Nakamura T, Kramer RH. 1994. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 269: 31807-31813.
Miller WM, Wilke CR, Blanch HW. 1987. Effects of dissolved oxygen concentration on hybridoma growth and metabolism in continuous culture. J. Cell. Physiol. 132: 524-530.
Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. 2010. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol. Cancer Ther. 9: 1544-1553.
Nakamura T, Matsumoto K, Kiritoshi A, Tano Y. 1997. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 57: 3305-3313.
Nakamura T, Nawa K, Ichihara A. 1984. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 122:1450-1459.
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. 1989. Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443.
Ozturk SS and Palsson BO. 1990. Effects of dissolved oxygen on hybridoma cell growth, metabolism, and antibody production kinetics in continuous culture. Biotechnol. Prog. 6:437-446.
Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. 1994. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 54: 5895-5901.
Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. 2009. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 69: 8009-8016.
Rafferty B, Maile P, Rigsby P, Gaines Das RE, Robinson CJ. 2001. International standards for hepatocyte growth factor/scatter factor: initial assessment of candidate materials and their evaluation by multicentre collaborative study. J. Immunol. Methods 258: 1-11.
Renard JM, Spagnoli R, Mazier C, Salles MF, Mandine E. 1988. Evidence that monoclonal antibody production kinetics is related to the integral of the viable cells in batch systems. Biotechnol. Lett. 10: 91-96.
Rosen EM, Laterra J, Joseph A, Jin L, Fuchs A, Way D, et al. 1996. Scatter factor expression and regulation in human glial tumors. Int. J. Cancer 67: 248-255.
Rubin JS, Bottaro DP, Aaronson SA. 1993. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta 1155: 357-371.
Schmid G, Blanch HW. Wilke CR. 1990. Hybridoma growth, metabolism, and product formation in HEPES-buffered medium: II. Effect of pH. Biotechnol. Lett. 12: 633-638.
Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. 1994. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 263: 98-101.
Walsh G, Jefferis R. 2006. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24: 12411252.